The estimated Net Worth of Anthony S Marucci is at least $7.28 Million dollars as of 15 August 2022. Mr. Marucci owns over 120,000 units of Celldex Therapeutics stock worth over $6,149,895 and over the last 16 years he sold CLDX stock worth over $0. In addition, he makes $1,128,320 as President, Chief Executive Officer und Director at Celldex Therapeutics.
Anthony has made over 7 trades of the Celldex Therapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 120,000 units of CLDX stock worth $614,400 on 15 August 2022.
The largest trade he's ever made was exercising 120,000 units of Celldex Therapeutics stock on 15 August 2022 worth over $614,400. On average, Anthony trades about 7,556 units every 194 days since 2009. As of 15 August 2022 he still owns at least 147,692 units of Celldex Therapeutics stock.
You can see the complete history of Mr. Marucci stock trades at the bottom of the page.
Anthony S. Marucci serves as President, Chief Executive Officer, Director of the Company. Mr. Marucci has held a number of roles with Celldex, including as a founder, Vice President, Chief Financial Officer, Treasurer and Secretary. In addition, he was Treasurer of Medarex, Inc. (now a part of Bristol-Myers Squibb Co.) from December 1998 to March 2004. Mr. Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. Mr. Marucci is a member of the Board of Trustees of BioNJ Inc. and also served as its Treasurer through 2010. Mr. Marucci is a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci received his M.B.A. from Columbia University and his M.H.L. from Brown University.
As the President, Chief Executive Officer und Director of Celldex Therapeutics, the total compensation of Anthony Marucci at Celldex Therapeutics is $1,128,320. There are 1 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
Anthony Marucci is 58, he's been the President, Chief Executive Officer und Director of Celldex Therapeutics since 2008. There are 15 older and 9 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Anthony's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil und Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: